Lostad T12.5

Rx

Indications:

• Hypertension and chronic heart failure in patients when treatment with ACE inhibitors is not considered suitable or contraindication with ACE inhibitors and to reduce the risk of stroke in patients with left ventricular hypertrophy.
• Diabetic nephropathy with hypertension (as serum creatinine is 1.3 – 3.0 mg/dl in patients ≤ 60 kg and 1.5 – 3.0 mg/dl in males > 60 kg and proteinuria).

Dosage:

Hypertension:

Adults:

• The usual dose: 50 mg once daily. The dose may be increased, if necessary, to 100 mg daily as a single dose or in two divided doses.
• Patients with intravascular fluid depletion, hepatic impairment: An initial dose of 25 mg once daily.

Children ( ≥ 6 years of age with hypertension):

• Those weighing 20 – 50 kg: a usual initial oral dose of 0.7 mg/kg (maximum 25 mg) daily, adjusted if necessary to a maximum 50 mg daily.
• Those weighing over 50 kg: an initial oral dose 1.4 mg/kg (maximum 50 mg) daily, adjusted if necessary to a maximum 100 mg daily.
• Losartan is not recommended in children with hepatic impairment.

Heart failure: Patients aged 60 years and over: an initial dose of 12.5 mg is given once daily, and may be doubled at weekly intervals to a usual maintenance dose of 50 mg once daily.

Nephropathy in type 2 diabetic patients: An initial dose of 50 mg once daily, increased to 100 mg once daily depending on the blood pressure.

Usage:

Lostad T12.5 is administered orally.

• Hypersensitivity to any of the active substance or excipients.
• Second and third trimester of pregnancy.
• Severe hepatic impairment.
• The concomitant use of losartan with aliskiren-containing products is contraindicate d in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m²).

Common:
Hypotension; Insomnia, dizziness; Hyperkalemia; Diarrhoea, dyspepsia; Slight decreases in hemoglobin and hematocrit; Back pain, leg pain, myalgia; Hypouricemia (if used in high does); Cough (less than ACE inhibitors), nasal congestion, sinusitis.

• Losartan should be used with caution in patients with renal artery stenosis.
• The reduced doses may be required in patients with renal impairment and should be considered in patients with hepatic impairment; Dose adjusted in patients with volume depletion.
• Serum-potassium concentrations should be monitored, especially in the elderly and patients with renal impairment, and the concomitant use of potassium-sparing diuretics should generally be avoided.
• Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
• Product is not recommended for breast-feeding women.
• When driving vehicles or operating machinery it must be borne in mind that dizziness or drowsiness may occasionally occur.